Scientific Opinion on the substantiation of a health claim related to iron and contribution to normal cognitive development pursuant to Article 14 of Regulation (EC) No 1924/2006

Tabs

Article
Panel on Dietetic Products, Nutrition and Allergies
EFSA Journal
EFSA Journal 2013;11(7):3335 [10 pp.].
doi
10.2903/j.efsa.2013.3335
Panel members at the time of adoption
Carlo Agostoni, Roberto Berni Canani, Susan Fairweather-Tait, Marina Heinonen, Hannu Korhonen, Sébastien La Vieille, Rosangela Marchelli, Ambroise Martin, Androniki Naska, Monika Neuhäuser-Berthold, Grażyna Nowicka, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Martin Stern, Sean (J.J.) Strain, Inge Tetens, Daniel Tomé, Dominique Turck and Hans Verhagen
Acknowledgements

The Panel wishes to thank the members of the Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Marina Heinonen, Ambroise Martin, Hildegard Przyrembel, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Sean (J.J.) Strain, Inge Tetens, Hendrik Van Loveren, Hans Verhagen and Peter Willatts for the preparatory work on this scientific opinion.

Contact
Type
Opinion of the Scientific Committee/Scientific Panel
On request from
the Competent Authority of France following an application by IDACE
Question Number
EFSA-Q-2008-199
Adopted
11 July 2013
Published
26 July 2013
Affiliation
European Food Safety Authority (EFSA), Parma, Italy
Note
Download Article (185.49 KB)
Abstract

Following an application from IDACE, submitted pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to iron and contribution to normal cognitive development. The food constituent, iron, which is the subject of the health claim, is sufficiently characterised. Contribution to normal cognitive development is a beneficial physiological effect for infants and young children. A claim on iron and cognitive development in children (up to 18 years) has already been assessed with a favourable outcome. The Panel notes that the role of iron in normal cognitive development also applies to infants and young children (from birth to three years). The Panel concludes that a cause and effect relationship has been established between dietary intake of iron and contribution to normal cognitive development. The following wording reflects the scientific evidence: “Iron contributes to normal cognitive development”. The target population is infants and children up to three years.

Summary

Following an application from IDACE, submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to iron and contribution to normal cognitive development.

The scope of the application was proposed to fall under a health claim referring to children’s development and health.

The food constituent that is the subject of the health claim is iron, which is a well recognised nutrient and is measurable in foods by established methods. The Panel considers that iron is sufficiently characterised.

The claimed effect proposed by the applicant is “important for the cognitive development of infants and young children”. The target population proposed by the applicant is “infants and young children from birth to three years of age”. The Panel considers that contribution to normal cognitive development is a beneficial physiological effect for infants and young children.

The evidence provided by consensus opinions/reports from authoritative bodies and reviews shows that there is consensus on the role of iron in cognitive development and function. Insufficient iron intake results in iron deficiency signs and symptoms, including anaemia, impaired psychomotor development and impaired cognitive performance. The cognitive deficiency symptoms observed in subjects with iron-deficiency anaemia include deficits in attention, perceptual motor speed, memory and verbal fluency.

A claim on iron and cognitive development in children (up to 18 years) has already been assessed by the Panel with a favourable outcome. The Panel notes that the role of iron in normal cognitive development also applies to infants and young children (from birth to three years).

The Panel concludes that a cause and effect relationship has been established between dietary intake of iron and contribution to normal cognitive development.

The following wording reflects the scientific evidence: “Iron contributes to normal cognitive development”.

The Panel considers that, in order to bear the claim, follow-on formulae should comply with the criteria of composition of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally complete foods for special medical purposes intended for use by infants and nutritionally complete foods for special medical purposes other than those intended for use by infants should comply with the criteria of composition of these foods as laid down in Directive 1999/21/EC; processed cereal-based foods for infants and young children should comply with the criteria of composition of these foods as laid down in Directive 2006/125/EC; other foodstuffs intended for infants and young children should provide at least 15 % of the reference values for nutrition labelling for foods intended for infants and young children as laid down in Directive 2006/125/EC. Such amounts can be easily consumed as part of a balanced diet. The target population is infants and children up to three years. No Upper Tolerable Intake Level has been set for iron in this age group.

Keywords
Iron, infants, children, cognitive development, health claims
Print on demand
Number of Pages
10